SIREN : 811138973
MAROMMEDIS is a French company founded 11 years ago, specialized in the sector Hypermarchés. Based in MAROMME (76150), this company of category GE shows in 2024 a revenue of 17.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17 598 153 € | 18 918 827 € | 19 096 612 € | 18 356 679 € | 18 962 244 € | 19 503 319 € | 18 202 886 € | 16 299 629 € | 16 311 166 € | 4 300 254 € |
| Net income | 965 924 € | 735 092 € | 194 110 € | 716 561 € | -559 762 € | -423 074 € | 1 103 049 € | -1 895 965 € | -1 224 083 € | -515 152 € |
| EBITDA | -753 250 € | -920 000 € | -1 259 195 € | -418 272 € | -424 906 € | -271 802 € | -840 839 € | -1 616 557 € | -1 145 286 € | -889 100 € |
| Net margin | 5.5% | 3.9% | 1.0% | 3.9% | -3.0% | -2.2% | 6.1% | -11.6% | -7.5% | -12.0% |
In 2024, MAROMMEDIS achieves revenue of 17.6 M€. Over the period 2015-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +16.9%. Slight decline of -7% vs 2023. After deducting consumption (13.7 M€), gross margin stands at 3.9 M€, i.e. a rate of 22%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -753 k€, representing -4.3% of revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 966 k€, i.e. 5.5% of revenue. This profit can be retained or distributed to shareholders.
17 598 153 €
3 876 672 €
-753 250 €
-726 837 €
965 924 €
-4.3%
The debt ratio (= Financial debt / Equity x 100) stands at -127%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -33%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.2 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 5.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
-126.985%
-32.921%
5.384%
1.204
In 2024, the debt ratio of MAROMMEDIS (-126.98) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of MAROMMEDIS (-32.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of MAROMMEDIS (1.20) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 102.39. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
102.394
-20.84
In 2024, the liquidity ratio of MAROMMEDIS (102.39) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of MAROMMEDIS (-20.8x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 2 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 45 days. Excellent situation: suppliers finance 43 days of the operating cycle (retail model). Inventory turnover is 17 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 35 days of revenue, i.e. 1.7 M€ to permanently finance. Over 2015-2024, WCR increased by +48%, requiring additional financing.
1 729 019 €
2 j
45 j
17 j
35 j
Based on 551 transactions of similar company sales in 2024, the value of MAROMMEDIS is estimated at 4 678 535 € (range 2 335 337€ - 9 541 684€). The price/revenue ratio is 0.23x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 551 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MAROMMEDIS with other companies in the same sector:
The revenue of MAROMMEDIS in 2024 is 17.6 M€.
Yes, MAROMMEDIS generated a net profit of 966 k€ in 2024.
The headquarters of MAROMMEDIS is located in MAROMME (76150), in the department Seine-Maritime.
The tax return of MAROMMEDIS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MAROMMEDIS operates in the sector Hypermarchés (NAF code 47.11F). See the 'Sector positioning' section above to compare the company with its competitors.